Current therapeutic options for liver metastasis;Alternativas terapéuticas actuales de las metástasis hepáticas

Revista Medica de Chile

Volumn 136, Issue 3, 2008, Pages 376-384

  Martínez Castillo, Jorge ^a,b   Jarufe C, Nicolás ^a   González D, Robinson ^a   Álvarez Z, Manuel ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Hepatectomy; Liver neoplasms; Neoplasm metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLOXURIDINE; FLUOROURACIL; IRINOTECAN;

CANCER STAGING; CARCINOMA; CATHETER ABLATION; COLORECTAL TUMOR; CRYOSURGERY; HUMAN; LIVER RESECTION; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CRYOSURGERY; FLOXURIDINE; FLUOROURACIL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 44849122713     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. SEYMOUR K, CHARNLEY R. Evidence that metastasis is less common in cirrhotic than normal liver: a systematic review of post-mortem case-control studies. Br J Surg 1999; 86: 1237-43.
2. PEREIRA-LIMA JE, LICHTENFELS E, BARBOSA FS, ZETTLER CG, KULCZYNSKI JM. Prevalence study of metastases in cirrhotic livers. Hepatogastroenterology 2003; 50: 1490-5.
3. WASHINGTON K. Pathology of primary and secondary liver tumors. En Clavien P.A. Malignant liver tumors. Current and emerging therapies. Blackwell Science, Massachussets, London. 1999; 137-49.
4. BECKINGHAM I, KRIGE J. Liver tumours. BMJ 2001; 322: 477-80.
5. PENNA C. Prise en charge des patients ayant un cancer du foie. Les métastases hépatiques des cancers colo-rectaux. Bull Cancer 2003; 90: 79-83.
6. TOPHAN C, ADAM R. Oncosurgery: a new reality in metastatic colorectal carcinoma. Semin Oncol 2002; 29: 3-10.
7. WEITZ J, BLUMGART LH, FONG Y, JARNAGIN WR, D'ANGELICA M, HARRISON LE ET AL. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 2005; 241: 269-76.
8. ADAM R, CHICHE L, ALOIA T, ELIAS D, SALMON R, RIVOIRE M ET AL. Hepatic resection for noncolorectal nonendocrine liver metastases. Analysis of 1452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-35.
9. IHSE I, PERSSON B, TIBBLIN S. Neuroendocrine metastases of the liver. World J Surg 1995; 19: 76-82.
10. BUTLER J, ATTIYEH F, DALY JM. Hepatic resection for metastases of the colon and rectum. Surg Gyn Obstet 1986; 162: 109-13.
11. SCHEELE J, STANGL R, ALTENDORF-H OFMANN A, GALL F. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110: 13-29.
12. NORDLINGER B, GUIGUET M, VAILLANT JC, BALLADUR P, BOUDJEMA K, BACHELLIER P ET AL. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-62.
13. FONG Y, FORTNER J, SUN R, BRENNAN M, BLUMGART L. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18.
14. MINAGAWA M, MAKUUCHI M, TORZILLI G, TAKAYAMA T, KAWASAKI S, KOSUGE T ET AL. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Long-term results. Ann Surg 2000; 231: 487-99.
15. HAMADY Z, CAMERON IC, WYATT J, PRASAD RK, TOOGOOD GJ, LODGE JP. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1 cm rule. Eur J Surg Oncol 2006; 32: 557-63.
16. JONAS S, THELEN A, BENCKERT C, SPINELLI A, SAMMAIN S, NEUMANN U ET AL. Extended resections of liver metastases from colorectal cancer. World J Surg 2007; 31: 511-21.
17. STANGL R, ALTENDORF-HOFMANN A, CHARNLEY RM, SCHEELE J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-10.
18. DEMATTEO R, PALESE C, JARNAGIN W, SUN R, BLUMGART LH, FONG Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000; 4: 178-84.
19. CHOTI M, SITZMANN J, TIBURI M, SUMETCHOTIMETHA W, RANGSIN R, SCHULICK R ET AL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-66.
20. MIGNON M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62: 51-58.
21. VAN VILSTEREN FG, BASKIN-BEY ES, NAGORNEY DM, SANDERSON SO, KREMERS WK, ROSEN CB ET AL. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl 2006; 12: 448-56.
22. SELZNER M, MORSE MA, VREDENBURGH JJ, MEYERS WC, CLAVIEN PA. Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000; 127: 383-9.
23. VLASTOS G, SMITH D, SINGLETARY S, MIRZA N, TUTTLE T, POPAT R ET AL. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004; 11: 869-74.
24. SHIRABE K, SHIMADA M, MATSUMATA T, HIGASHI H, YAKEISHI Y, WAKIYAMA S ET AL. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 2003; 50: 1560-3.
25. LIVRAGHI T, VETTORI C, LAZZARONI S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991; 179: 709-12.
26. GIOVANNINI M. Percutaneous alcohol ablation for liver metastasis. Semin Oncol 2002; 2: 192-5.
27. BILCHIK A, WOOD T, ALLEGRA D. Radiofrequency ablation of unresectable hepatic malignancies: Lessons learned. The Oncologist 2001; 6: 24-33.
28. ABDALLA E, VAUTHEY J, ELLIS L, ELLIS V, POLLOCK R, BROGLIO K ET AL. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-25.
29. YEH K, FORTUNATO L, HOFFMAN J, EISENBERG B. Cryosurgical ablation of hepatic metastases from colorectal carcinomas. Am Surg 1997; 63: 63-8.
30. BARBER F, MAVLIGIT G, KURZROCK R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004; 30: 425-36.
31. COHEN A, KEMENY N. An update on hepatic arterial infusion chemotherapy for colorectal cancer. The Oncologist 2003; 8: 553-66.
32. MOERTEL C, FLEMING T, MACDONALD J, HALLER D, LAURIE J, GOODMAN P ET AL. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
33. ADVANCED COLORECTAL CANCER META-ANALYSIS PROJECT . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
34. VAN CUTSEM E, TWELVES C, CASSIDY J, ALLMAN D, BAJETTA E, BOYER M ET AL. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
35. SALTZ L, COX J, BLANKE C, ROSEN L, FEHRENBACHER L, MOORE M ET AL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
36. ROTHENBERG M, OZA A, BIGELOW R, BERLIN J, MARSHALL J, RAMANATHAN R ET AL. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-69.
37. ADAM R, DELVART V, PASCAL G, VALEANU A, CASTAING D, AZOULAY D ET AL. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57.
38. IGNOFFO RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004; 61(21 Suppl 5):S21-6.
39. HURWITZ H, FEHRENBACHER L, NOVOTNY W, CARTWRIGHT T, HAINSWORTH J, HEIM W ET AL. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
40. REYNOLDS N, WAGSTAFF AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004; 64: 109-18.